{"id":"placebo-matched-phentermine-topiramate","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Paresthesia"},{"rate":"10-15","effect":"Cognitive dysfunction/memory impairment"},{"rate":"15-20","effect":"Insomnia"},{"rate":"10-15","effect":"Tachycardia"},{"rate":"10-15","effect":"Dry mouth"},{"rate":"10-15","effect":"Constipation"},{"rate":"10-15","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Phentermine acts as a sympathomimetic amine that stimulates the release of norepinephrine in the hypothalamus, reducing appetite and increasing energy expenditure. Topiramate enhances weight loss through multiple mechanisms including carbonic anhydrase inhibition, potentiation of GABA signaling, and antagonism of kainate/AMPA glutamate receptors, which collectively promote satiety and reduce food intake. The combination produces synergistic weight loss effects beyond either agent alone.","oneSentence":"Phentermine/topiramate is a combination that suppresses appetite through sympathomimetic stimulation and enhances satiety through carbonic anhydrase inhibition and GABAergic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:37.471Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in obese or overweight patients with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT06299891","phase":"PHASE2","title":"Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2025-03-01","conditions":"Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma","enrollment":24},{"nctId":"NCT04721873","phase":"PHASE2","title":"Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2020-12-18","conditions":"Colitis, Ulcerative, Obesity","enrollment":40},{"nctId":"NCT01834404","phase":"PHASE4","title":"Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-04","conditions":"Obesity","enrollment":24},{"nctId":"NCT01087736","phase":"PHASE4","title":"Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-04","conditions":"PTSD, Alcohol Abuse, Alcoholism","enrollment":30},{"nctId":"NCT00554216","phase":"PHASE3","title":"Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2007-11","conditions":"Obesity","enrollment":1267},{"nctId":"NCT00486291","phase":"PHASE2","title":"Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2007-06","conditions":"Type 2 Diabetes Mellitus","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matched phentermine/topiramate","genericName":"Placebo matched phentermine/topiramate","companyName":"VIVUS LLC","companyId":"vivus-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phentermine/topiramate is a combination that suppresses appetite through sympathomimetic stimulation and enhances satiety through carbonic anhydrase inhibition and GABAergic effects. Used for Chronic weight management in obese or overweight patients with weight-related comorbidities.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}